Access cutting-edge congenital central hypoventilation syndrome treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Philadelphia location
Preparing your pre-screening questions…
Access congenital central hypoventilation syndrome specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related congenital central hypoventilation syndrome treatment provided free
Check if you qualify for this congenital central hypoventilation syndrome clinical trial in Philadelphia, PA
No-Cost Study Care
Local to Philadelphia
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that frequently alters oxygen delivery to the brain. In CCHS, neurocognitive function has been of great concern because of the potential for repeated hypoxemia and hypercarbia in activities of daily living in addition to hypoventilation with related hypoxemia and hypercarbia during sleep. As the world's leading referral center for CCHS, the Center for Autonomic Medicine in Pediatrics (CAMP) is engaged in ongoing research to identify factors that impact neurocognitive performance in patients with CCHS in order to optimize clinical management and improve long term neurocognitive outcomes. The purpose of this IRB-approved research study is to implement the NIH Toolbox as a standard measurement of cognitive health in patients with CCHS. Further, the study aims to determine how intrinsic and extrinsic disease factors such as age at diagnosis, PHOX2B mutation type and genotype, and nature of past and present artificial respiratory intervention affect the NIH Toolbox Cognitive scores of individuals with CCHS. Eligible participants will complete a 45-minute NIH Toolbox assessment and parents (or adult participants) will complete an associated, 15-minute Research Electronic Data Capture (REDCap) questionnaire.
Sponsor: Debra Weese-Mayer
Yes, this clinical trial (NCT03568669) has an active research site in Philadelphia, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for congenital central hypoventilation syndrome treatment options in Philadelphia, PA, this clinical trial (NCT03568669) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced congenital central hypoventilation syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all congenital central hypoventilation syndrome clinical trials near you to find additional studies recruiting in your area.
See all rheumatoid arthritis clinical trials recruiting in Philadelphia — not just this study.
Browse Rheumatoid Arthritis Trials in Philadelphia →